Skip to content
93 735193 7351

Drawing based on the label description. No photo yet.

93 7351 93 7351 pill

Pill with imprint 93 7351 93 7351 is gray & white, capsule, 19 mm and has been identified as Lansoprazole 30 mg. It is used for acid reflux (GERD), ulcers and stomach ulcers. It is supplied by Proficient Rx LP.

Lansoprazole 30 mg

Imprint
93 7351 93 7351
Strength
30 mg
Used for
Acid reflux (GERD), ulcers and stomach ulcers
Color
Gray, White
Shape
Capsule / oblong
Size
19 mm
Score
No score line
Form
Capsule, delayed release
Manufacturer
Proficient Rx LP
Drug class
Acid reducer (proton pump inhibitor)
NDC
63187-152, 0093-7351, 63187-152-30, 0093-7351-56

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Lansoprazole pills and guides

What is Lansoprazole used for?

Lansoprazole is used for acid reflux (GERD), ulcers, stomach ulcers and H. pylori infection.

Medicine type
Acid reducer (proton pump inhibitor)
Official uses from the US prescribing label

Treatment of Active Duodenal Ulcer

Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer.

Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence

Triple Therapy: Lansoprazole delayed-release orally disintegrating tablets /amoxicillin/clarithromycin

Lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Please refer to the full prescribing information for amoxicillin and clarithromycin.

Dual Therapy: Lansoprazole delayed-release orally disintegrating tablets/amoxicillin

Lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin prescribing information, Microbiology section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Please refer to the full prescribing information for amoxicillin.

Maintenance of Healed Duodenal Ulcers

Lansoprazole delayed-release orally disintegrating tablets are indicated in adults to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months.

Treatment of Active Benign Gastric Ulcer

Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for short-term treatment (up to eight weeks) for healing and symptom relief of active benign gastric ulcer.

Healing of NSAID-Associated Gastric Ulcer

Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond eight weeks.

Risk Reduction of NSAID-Associated Gastric Ulcer

Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks.

Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD)

Lansoprazole delayed-release orally disintegrating tablets are indicated for short-term treatment in adults and pediatric patients 12 to 17 years of age (up to eight weeks) and pediatric patients one to 11 years of age (up to 12 weeks) for the treatment of heartburn and other symptoms associated with GERD.

Treatment of Erosive Esophagitis (EE)

Lansoprazole delayed-release orally disintegrating tablets are indicated for short-term treatment in adults and pediatric patients 12 to 17 years of age (up to eight weeks) and pediatric patients one to 11 years of age (up to 12 weeks) for healing and symptom relief of all grades of EE. For adults who do not heal with lansoprazole delayed-release orally disintegrating tablets for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment. If there is a recurrence of erosive esophagitis an additional eight week course of lansoprazole delayed-release orally disintegrating tablets may be considered.

Maintenance of Healing of EE

Lansoprazole delayed-release orally disintegrating tablets are indicated in adults to maintain healing of EE. Controlled studies did not extend beyond 12 months.

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES)

Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

From the FDA-approved label on DailyMed (published Sep 02, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows 93 7351 93 7351. The parts can be split between the two sides, so turn the pill over and check both.
  • It is gray & white, capsule, 19 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Lansoprazole

Inactive: Ferrosoferric Oxide, Gelatin, Unspecified, Hypromellose 2910 (6 Mpa.s), Magnesium Carbonate, Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Type A, Propylene Glycol, Ferric Oxide Red, Shellac, Sucrose, Starch, Corn, Talc, Titanium Dioxide, Triethyl Citrate, Potassium Hydroxide

Also distributed by

Teva Pharmaceuticals Usa, Inc.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Lansoprazole pills